{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:32:59Z","timestamp":1792308779319,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jdermsci.2014.04.002","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T04:46:21Z","timestamp":1397623581000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Vasoconstriction and anti-inflammatory properties of the selective \u03b1-adrenergic receptor agonist brimonidine"],"prefix":"10.1016","volume":"75","author":[{"given":"David","family":"Piwnica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Rosignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine Thibaut","family":"de M\u00e9nonville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Schuppli Nollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Roye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Jomard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2014.04.002_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","article-title":"Etiology, pathogenesis, and subtype classification","volume":"51","author":"Crawford","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0015","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","article-title":"Standard grading system for rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0020","first-page":"43","article-title":"Standard management options for rosacea, Part I: overview and broad spectrum of care","volume":"84","author":"Odom","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1468-3083.2005.01216.x","article-title":"Rosacea and its management: an overview","volume":"19","author":"Gupta","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdermsci.2014.04.002_bib0030","first-page":"26","article-title":"Advances in understanding and managing rosacea: part 2. The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"Clinical, cellular and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Pathophysiology and treatment","volume":"130","author":"Wilkin","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0045","first-page":"16","article-title":"Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.jdermsci.2014.04.002_bib0050","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"3S","key":"10.1016\/j.jdermsci.2014.04.002_bib0055","first-page":"1","article-title":"An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea","volume":"91","author":"Del Rosso","year":"2013","journal-title":"Cutis"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0060","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2005.10.009","article-title":"Videocapillaroscopic alterations in erythematotelangiectatic rosacea","volume":"54","author":"Rosina","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","article-title":"Neurovascular and neuroimmune aspects in the pathophysiology of rosacea","volume":"15","author":"Schwab","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"August","key":"10.1016\/j.jdermsci.2014.04.002_bib0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","article-title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0075","series-title":"Poster presented at: Society for Investigative Dermatology Annual Meeting","first-page":"P093","article-title":"Mast cell and neuropeptide expression are increased in erythematotelangiectatic rosacea in comparison to telangiectatic photoaging","author":"Helfrich","year":"2012"},{"issue":"January","key":"10.1016\/j.jdermsci.2014.04.002_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bmj.1.6000.21","article-title":"Rosacea and migraine","volume":"3","author":"Tan","year":"1976","journal-title":"Br Med J"},{"issue":"September (3)","key":"10.1016\/j.jdermsci.2014.04.002_bib0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2013.03.027","article-title":"Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom","volume":"69","author":"Spoendlin","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jdermsci.2014.04.002_bib0090","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archderm.143.11.1369","article-title":"Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline","volume":"143","author":"Shanler","year":"2007","journal-title":"Arch Dermatol"},{"issue":"July","key":"10.1016\/j.jdermsci.2014.04.002_bib0095","first-page":"31","article-title":"Rosacea therapy: current approaches and future directions","author":"Bikowski","year":"2012","journal-title":"Pract Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/14740331003709736","article-title":"Brimonidine for glaucoma","volume":"9","author":"Rahman","year":"2010","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.jdermsci.2014.04.002_bib0110","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0039-6257(96)82030-3","article-title":"A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III","volume":"41","author":"Serle","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","article-title":"Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group","volume":"127","author":"Katz","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jdermsci.2014.04.002_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/14656566.1.4.815","article-title":"The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use","volume":"1","author":"Cantor","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0125","unstructured":"Mirvaso\u00ae Prescribing Information."},{"issue":"1","key":"10.1016\/j.jdermsci.2014.04.002_bib0130","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-labeled study","volume":"13","author":"Moore","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0135","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0140","first-page":"S1","article-title":"The alpha adrenergic receptor agonist oxymetazoline inhibits temperature-induced vasodilation and LL-37 induced skin inflammation","volume":"132","author":"Hsia","year":"2012","journal-title":"J Investig Dermatol"},{"issue":"November (11)","key":"10.1016\/j.jdermsci.2014.04.002_bib0145","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.12121","article-title":"Rosacea under the microscope: characteristic histological findings","volume":"27","author":"Cribier","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdermsci.2014.04.002_bib0150","first-page":"S209","article-title":"The alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB-induced sunburn model","volume":"133","author":"Tian","year":"2013","journal-title":"J Investig Dermatol"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181114000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181114000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T22:26:31Z","timestamp":1538691991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181114000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0923181114000826"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2014.04.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasoconstriction and anti-inflammatory properties of the selective \u03b1-adrenergic receptor agonist brimonidine","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2014.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}